News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Tiotropium Appears to Cut Deaths, Cardiovascular Event Rates
January 6, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
MedPage Today -- Patients taking tiotropium bromide (Spiriva) for chronic obstructive pulmonary disease (COPD) appear to be at decreased risk for death and cardiovascular events compared with placebo, researchers said.
Twitter
LinkedIn
Facebook
Email
Print